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Defects of CoQ10 metabolism cause a variety of disorders ranging from isolated myopathy to 
multisystem involvement. ADCK3 is one of several genes associated with CoQ10 deficiency 
presenting with progressive cerebellar ataxia, epilepsy, migraine and psychiatric disorders. 
Diagnosis is challenging due to the wide clinical spectrum and overlap with other 
mitochondrial disorders. 
Methods  
We provide a detailed description of 3 new and one previously reported patients from three 
families with novel and known mutations in the ADCK3 gene focussing on the epileptic 
semiology and response to treatment.  In 3 patients, we used exome sequencing to identify the 
ADCK3 mutation and in 2 measurement of skeletal muscle CoQ10 was performed.  
Results  
All four patients presented with childhood onset epilepsy and progressive cerebellar ataxia. 
Three patients had epilepsia partialis continua and stroke-like episodes affecting the posterior 
brain. EEG showed focal epileptic activity in the occipital and temporal lobes. Genetic 
investigation revealed ADCK3 mutations in all patients including a novel change in exon 15: 
c.T1732G, p.F578V. There was no apparent genotype-phenotype correlation. 
Conclusion  
ADCK3 mutations cause a combination of progressive ataxia and acute epileptic 
encephalopathy with stroke-like episodes. The clinical, radiological and electrophysiological 
features of this disorder mimic the phenotype of polymerase gamma (POLG) related 
encephalopathy. We suggest that ADCK3 mutations should be considered in the differential 
diagnosis of mitochondrial encephalopathy with POLG-like features.  
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INTRODUCTION:   
Coenzyme Q10 (CoQ10), the major form of endogenous ubiquinone in humans, is a fat-
soluble substance present in most eukaryotic cells. It is synthesized in the mitochondrial inner 
membrane and comprises a benzoquinone ring, derived from tyrosine or phenylalanine and 
decaprenyl tail, which is synthesized in the cytosol via the mevalonate pathway. The process 
of CoQ10 synthesis is complex and involves several enzymatic steps (1). The major function 
of CoQ10 is to transport electrons from complexes I and II to complex III in the respiratory 
chain, but it is also required for pyrimidine nucleoside biosynthesis and is involved in 
modulating apoptosis (2). It is still not clear whether the pathophysiological mechanism of 
CoQ10 deficiency reflects the bioenergetic defect or to impairment of its other functions (3). 
Thirteen genes are known to be involved in the biosynthesis of human CoQ10 (PDSS, PDSS2, 
COQ2, COQ3, COQ4, COQ5, COQ6, COQ7, ADCK3, ADCK4, COQ9, COQ10a, COQ10B). 
Mutations in eight of them (PDSS1, PDSS2, COQ2, COQ4, COQ6, ADCK3, ADCK4, COQ9)  
are associated with human diseases (4). CoQ10 deficiency comprises a continuum of 
overlapping phenotypes classified either as primary, i.e. caused by mutations in genes 
involved in CoQ10 synthesis, or secondary, those caused by defects in genes unrelated to 
CoQ10 biosynthesis, but which result in CoQ10 deficiency.  
Five major phenotypes have been described (3) with primary CoQ10 deficiency including 
myopathic and encephalopathic forms, but overlap is common. Diagnosis of CoQ10 
deficiency disorders is challenging especially in the paediatric population where patients often 
present with non-specific phenotypes such as neonatal seizures or encephalopathy.  
We report a series of 4 patients with ADCK3 mutations (MIM606980) and CoQ10 deficiency 
presenting with a phenotype resembling that seen in polymerase gamma (POLG) related 
disease (5). The clinical features of these cases are compared with previously reported cases 
with particular focus in the seizures frequency, semiology and response to treatment.   
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PATIENTS AND METHODS: 
Our study was approved by the Regional Committee for Medical and Health Research Ethics, 
Western Norway (IRB00001872). All study participants provided written informed consent. 
The clinical and genetic features of the patients are summarized in table 1. 
Case reports 
Patient 1 is a 35 year old woman, the second child of non-consanguineous parents. After a 
normal birth and early psychomotor development, she developed focal and secondarily 
generalized seizures aged 7 years. From her early teens, she became increasingly ataxic and 
developed a fine tremor involving the head and upper extremities. Examination at the age of 
34 years showed cerebellar dysarthria and mild gait and appendicular ataxia. Muscle tone and 
power, deep tendon reflexes and Romberg test were all normal. At 34 she remains ambulatory 
and works full-time. Her inter-ictal EEG shows bilateral occipital and right temporal epileptic 
activity. MRI at the age 31 years showed mild cerebellar atrophy affecting mainly the 
superior vermis and high T2-signal symmetrically in the nuclei dentatii (“white teeth” sign). 
Treatment with Ubiquinone 300 mg 3 times daily for 6 months has not yet given any apparent 
improvement.  
Patient 2 is a 34 year old man, the third child of healthy parents. His similarly affected older 
sister died aged 22 years (Patient 3).  He was born at term after a normal pregnancy and 
delivery and walked aged 12 months, with an unsteady gait. He developed focal and 
generalized seizures aged 7 years. At age 8 had one episode of epilepsia partialis continua 
affecting the right arm and leg and a stroke-like episode with vomiting, headache and right 
hemiparesis. He also had migraine-like episodes at age of 18 with two episodes of severe 
headache with nausea leaving him bedridden for one day. He has been seizure free from the 
age of 29 years on lamotrigine and sodium valproate. He developed progressive ataxia from 
late teenage and examination aged 33 years showed marked scanning dysarthria, gait ataxia, 
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dysmetria, intension tremor and dysdiadochokinesia. He scored 11 points on the SARA scale 
(scale for assessment and rating of ataxia). Inter-ictal EEG shows focal, bilateral occipito-
temporal epileptic spikes. MRI of the brain showed cerebellar atrophy with “white teeth” sign 
and a focal, cortical stroke-like lesion in the right occipital lobe (figure 1A-C). Cerebral FDG-
PET showed cerebellar hypometabolism and focal, asymmetrical hypometabolism in the right 
occipital lesion (Figure 1D-E). Treatment with Ubiquinone 300 mg 3 times daily was started 
aged 33 years and at six month follow-his score had fallen to 6 points on the SARA scale. 
Both patient and family reported improved balance, coordination and daily function. MRI of 
the brain remained unchanged. 
Patient 3, the older sister of patient 2, was born at term after normal pregnancy and delivery. 
She developed normally until age 3 years when she developed motor difficulties, dysarthria, 
and progressive ataxia. She developed epilepsy aged 7 years, which was classified as focal 
with secondary generalization. EEG showed bilateral multifocal temporo-occipital epileptic 
spikes. Her ataxia worsened in her late teens and she developed tremor and cognitive 
impairment and was admitted repeatedly with status epilepticus and epilepsia partialis 
continua. MRI showed cerebellar atrophy with dentate hyperintensity and multiple bilateral 
cortical stroke-like lesions throughout the cortex. She died at the age of 22 years in intractable 
status epilepticus. 
Patient 4, a 22 years old women, has been published previously (6), but is included here with 
a more detailed clinical description. She is the first child of healthy non consanguineous 
parents. She developed motor difficulties and ataxia at 2 years and epilepsy at 3 that was 
classified as focal with secondary generalization. She became wheel chair dependant at age 
12, developed feeding difficulties requiring a gastrostomy and lost speech aged 14. She was 
admitted with status epilepticus and epilepsia partialis continua at age 14 and repeatedly 
thereafter. EEG showed left temporo-occipital activity.  MRI of the brain showed progressive 
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cerebellar atrophy with multiple bilateral cortical stroke-lesions in the occipital lobes. She 
started deoxyubiquinon 1000 mg per day aged 18 years without any significant improvement.  
 
Pathology 
Open muscle biopsy from vastus lateralis muscle was performed in patients 1, 2 and 4. 
Sequential histochemical assay of cytochrome oxidase (COX) and succinate dehydrogenase 
(SDH) activity was performed as previously described (7). Post-mortem examination of the 
brain was performed in patient-3 with standard histological methods including hematoxylin 




DNA was purified from blood using the Qiasymphony instrument (Qiagen, Hilden Germany) 
and muscle using a QIAamp DNA Mini Kit, Qiagen. MtDNA quantification and deletion 
assessment were performed in muscle DNA from patient 2 as previously described (8). 
Sanger sequencing of all coding exons of POLG and C10orf2 in patient 2 were normal. 
Whole exome sequencing was performed at HudsonAlpha Institute for Biotechnology 
(Huntsville, AL) using Roche-NimbleGen Sequence Capture EZ Exome v3 kit and paired-end 
100nt sequencing on the Illumina HiSeq. Data quality control and analysis was performed at 
our in-house pipeline as previously described (9).  
 
CoQ measurement  
CoQ10 was extracted from muscle homogenate as previously described (10) and its 








Muscle biopsies from patients 1 (32 years) and 4 (4 years) were unremarkable. The biopsy of 
patient 2 aged 23 years was similarly normal except for the presence of a single COX 
negative fibre.  
Post-mortem examination of the brain in patient 3 showed severe cerebellar atrophy and 
multifocal fibrotic infarct-like changes in the occipital and frontal cortex. Microscopic 
examination showed widespread, multifocal infarct-like changes throughout the cerebral 
cortex with neuronal loss and eosinophilic neuronal necrosis accompanied by astrocytic and 
microglial proliferation. Similar changes were also seen in the striatum and amygdala. In the 
cortex, neuronal loss affected predominantly the superficial (II-III) and deep (IV-V) cortical 
layers suggestive of laminar cortical necrosis. In the cerebellum and brainstem there was 
severe neuronal loss, eosinophilic neuronal necrosis and astrogliosis in the cerebellar cortex, 
affecting the Purkinje cells and neurons of the granule cell layer, dentate nucleus and inferior 
olivary nucleus of the medulla oblongata, whereas the pons and mesencephalic structures, 
including the substantia nigra, were preserved. 
 
CoQ10 levels:  
CoQ10 levels in frozen muscle samples from patients 1 and 2 (table 2) were low, both when 
related to protein content and the mitochondrial marker, citrate synthase (CS).  In patient 1 the 
CoQ10 concentration was 10% (normalized to protein) and 24% (normalized to CS) of 
control mean, while in patient 2 the concentration was 34% (normalized to protein) and 60% 




In families 1 and 2, ADCK3 mutations were identified by whole exome sequencing and 
confirmed by Sanger sequencing. In family 1, we found a homozygous mutation in exon 7: 
c.895C>T, which is predicted to give the amino acid change p.R299W. In patient 2, we found 
compound heterozygous mutations in exon 7: c.895C>T, p.R299W and exon 15:c.T1732G, 
p.F578V. We confirmed these were in trans by parental testing.  
The findings in family 3 have been reported previously: this patient was homozygous for 
c.895C>T, p.R299W. Currently, no connection between families 1 and 3 is known. The 
p.R299W mutation has been reported (6). The novel mutation p.F578V was absent in 400 in 
house controls and public databases including the 1000 genomes (11) and Exome 
Aggregation Consortium (ExAC), Cambridge, MA (URL: http://exac.broadinstitute.org) 
[June 2015 accessed]. Both the 299 and 578 residues are highly conserved and the mutations 
are predicted to affect the function of the protein by all protein predictions tools in the AlaMut 
software (Interactive Biosoftware, Rouen, France).     













We report 4 cases of CoQ10 deficiency due to mutations in the ADCK3 gene. The phenotype 
of our patients is compatible with earlier reports with all having a slowly progressive 
cerebellar ataxia with cerebellar atrophy. Additionally, our patients had epilepsy complicated 
by episodes of status epilepticus and clinical and imaging evidence of stroke-like episodes 
(4). While ataxia and encephalopathy are well-recognised features of CoQ10 deficiency, the 
epileptic semiology and stroke like episodes have not been systematically studied.  
Including our cases, a total of 78 patients from 45 families with primary CoQ10 deficiency 
have been reported (6, 12, 13). Epilepsy was present in 16 (20%) the majority of whom (11) 
had mutations in the ADCK3 gene suggesting that among patients with CoQ10 deficiency, 
those with ADCK3 mutations are particularly prone to epileptogenesis. Of the 11 patients with 
ADCK3 mutations and epilepsy, six had epilepsia partialis continua and 5 developed stroke-
like episodes with cortical lesions (Table 1&3) (14). EEG in our 4 patients showed that 
epileptic activity was focused in the occipital and temporal lobes. The combination of 
occipital predilection and an acute on chronic course with stroke-like lesions on MRI 
associated with periods of intense epileptic activity are similar to those seen in patients with 
POLG related disorders (5, 15, 16).  
While CoQ10 deficiency is a potentially treatable cause of disease, the steroid resistant 
nephrotic syndrome is reported to have a better treatment response than the neurological 
features. Seizures appear to respond poorly to oral CoQ10 supplementation (6, 12, 13, 17-25) 
and this may be due to reduced oral bioavailability. CoQ10 is poorly absorbed and as a lipid- 
soluble factor must be ingested together with significant quantities of fat to facilitate uptake. 
Bioavailability will depend both on dosage and how much crosses the blood-brain barrier 
(14). In the absence of formal trials these data are currently unavailable. Three of our patients 
have received oral deoxyubiquinone: one has not been on treatment long (patient 1) while 
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another (patient 4) started late and was already immobilised meaning that motor benefits 
would be hard to detect. Patient 2 showed a measurable improvement of ataxia. While 
improvement of the ataxia has been described previously (14), no definite antiepileptic effect 
has been shown. A potential preventative effect with regard to status epilepticus and 
associated stroke-like episodes cannot be excluded, but showing this will require systematic 
longitudinal studies, which are currently lacking. Moreover, as in our patient4, lack of clinical 
response in some patients may be due to delayed treatment start (18, 26). Thus, further studies 
are needed to characterise therapeutic responses to different CoQ10 derivatives, doses and 
organ-specific bioavailability.  
In conclusion, we report that patients with ADCK3 mutations can mimic the phenotype seen 
in POLG-related encephalopathy with progressive cerebellar ataxia complicated by epilepsy 
with occipital predilection, status epilepticus and associated stroke-like episodes. We 
recommend, therefore, mutations in ADCK3 gene be considered in the differential diagnosis 
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Table 1 Summary of cases reported in this paper 
 





   Current Death   Type Focus  
1 1 7 35  + - F,GTC Occ/Temp c.895C>T, p.R299W 
homozygous 
2 2 7 34  + + F,GTC,EPC Occ/Temp c.895C>T,p.R229W, 
c.1732T>G, p.F578V 
heterozygote 
2 3 3  22 + + F,GTC,EPC Occ/Temp c.895C>T,p.R229W, 
c.1732T>G, p.F578V 
heterozygote 
3 4 2 22  + + F,GTC,EPC Occ/Temp c.895C>T, p.R299W 
homozygous 
 
Abbreviations: F – focal seizure; GTC - generalised tonic clonic seizure; EPC- epilepsia partialis continua;  




Table 2. CoQ10 levels in patients 1 and 2 
  µg CoQ/g 
protein µg CoQ/CS Citrate synthase (CS) 
Patient 1  12.5 0.55 22.5 
Patient 2  40.9 1.36 30 
Control Mean 122 2.25 53 



























Abbreviation: NK-Not known; + Present; - Absent; EPC- epilepsia partialis continua; GTC- generalised tonic clonic seizure, 
 SLL-Stroke like lesions. 
 
Families Onset Age Cerebellar Cerebellar Epilepsy Epilepsy Mutations 
(N=Patients) (years) (years) ataxia atrophy 
 
classification 
 1 (4) 7-11 29-42 + + NK NK c.1398+2T>C homozygous 
2(1) 4 18 + + NK NK c.500_521 delinsTTG homozygous 
3(1) 5 17 + + NK NK p.Y514C/ p.T584del 
4(1) 3 30 + + NK NK p.L314_Q 360del/ p.G549S 
5(1) 1,5 16 + + SLL + GTC/ EPC p.E551K homozygous 
6(2) 1,5 13,14 + + SLL + GTC/ EPC p.R213W/ p.G272V 
7(1) 3 17 + + + Myoclonus p.G272D/ c.1812_13insG 
8(3) 3-9 26-31 + + + Myoclonus p.R348X homozygous 
9(2) 1,2 20,30 + + NK NK p.R348X/ p.L379X 
10(2) 15,18 46/NK + + + Myoclonus c.811C>T, p.R271C/ c.911G>A, pA304V 
11(1) 27 50 + + + Myoclonus c.911C>T, p.A304V homozygous 
12(1) 1 18 + + + NK c.895C>T, p.R299W homozygous 
13(2) 1,5 -2 20,26 + + - 
 
c.1286A>G, p.Y429C heterozygous 
14(2) 2-NK 20,32 + + NK 
 
p.T584delACC(c.1750_1752delACC) 
       
and p.P502R 







MRI (A-C) and FDG-PET (D-F) of the brain of patient 2 at the age of 34 years. A: sagittal T1-weighted image showing midline cerebellar 
atrophy, particularly of the superior vermis. B: axial T2-weighted image showing symmetrical hyperintense signal in the nucleus dentatus 
consistent with “white teeth” sign which often accompanies efferent cerebellar degeneration (i.e. loss of cerebellar output). C: axial T2-weighted 
image showing a stroke-like lesion in the right lateral occipital lobe. D-F: FDG-PET scan of the brain showing decreased glucose metabolism in 
the cerebellum (D and E) and right occipital lesion (F).    
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Figure 1 
 
